Naples prognostic score as a predictor of mortality in surgical aortic valve replacement.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Biomarkers in medicine Pub Date : 2024-09-12 DOI:10.1080/17520363.2024.2389035

Onur Erdoğan,Tuğba Erdoğan,Cafer Panç,İsmail Gürbak,Mehmet Ertürk

引用次数: 0

Abstract

Aim: Investigating the impact of nutritional and inflammatory status, assessed by the Naples-Prognostic-Score (NPS), on postoperative mortality in 173 older adults undergoing surgical aortic valve replacement(SAVR) for aortic stenosis(AS).Methods: Retrospective study calculating NPS from neutrophils/lymphocytes, lymphocytes/monocytes, total cholesterol and serum albumin.Results: Mean age was 69.39 ± 6.153 with 45.1% females. The post-operative mortality was 23.7% over a follow-up period of 50 ± 31 months. The 1-month mortality rate is 2.89%. High NPS significantly associated with increased mortality; multivariate logistic regression confirmed its independence (odds-ratio:3.494, 95% confidence-interval:1.555-7.849, p = 0.002). NPS cutoff of 2 showed 73.2% sensitivity, 56.8% specificity and area-under-the-curve of 0.758 for predicting all-cause mortality. Kaplan-Meier analysis supported lower NPS correlating with better survival.Conclusion: NPS independently predicts postoperative mortality in SAVR patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

那不勒斯预后评分作为外科主动脉瓣置换术死亡率的预测指标。

目的：在173名因主动脉瓣狭窄（AS）接受主动脉瓣置换术（SAVR）的老年人中，通过那不勒斯诊断评分（NPS）评估营养和炎症状态对术后死亡率的影响：回顾性研究：根据中性粒细胞/淋巴细胞、淋巴细胞/单核细胞、总胆固醇和血清白蛋白计算NPS：平均年龄（69.39±6.153）岁，女性占 45.1%。在 50 ± 31 个月的随访期间，术后死亡率为 23.7%。1 个月死亡率为 2.89%。高 NPS 与死亡率增加明显相关；多变量逻辑回归证实了其独立性（赔率：3.494，95% 置信区间：1.555-7.849，P = 0.002）。NPS 临界值为 2 时，预测全因死亡率的灵敏度为 73.2%，特异度为 56.8%，曲线下面积为 0.758。Kaplan-Meier分析支持较低的NPS与较好的生存率相关：结论：NPS可独立预测SAVR患者的术后死亡率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.